Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Antonio Passaro; Maise Al Bakir; Emily G Hamilton; Maximilian Diehn; Fabrice André; Sinchita Roy-Chowdhuri; Giannis Mountzios; Ignacio I Wistuba; Charles Swanton; Solange Peters

doi:10.1016/j.cell.2024.02.041

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Cell. 2024 Mar 28;187(7):1617-1635. doi: 10.1016/j.cell.2024.02.041.

Authors

Affiliations

¹ Division of Thoracic Oncology, European Institute of Oncology IRCCS, Milan, Italy.
² Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
³ Department of Radiation Oncology, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.
⁴ Gustave-Roussy Cancer Center, Paris Saclay University, Villejuif, France.
⁵ Department of Anatomic Pathology and Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Fourth Department of Medical Oncology and Clinical Trials Unit, Henry Dunant Hospital Center, Athens, Greece.
⁷ Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁸ Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK; Department of Oncology, University College London Hospitals, London, UK.
⁹ Department of Oncology, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland. Electronic address: solange.peters@chuv.ch.

Abstract

The integration of cancer biomarkers into oncology has revolutionized cancer treatment, yielding remarkable advancements in cancer therapeutics and the prognosis of cancer patients. The development of personalized medicine represents a turning point and a new paradigm in cancer management, as biomarkers enable oncologists to tailor treatments based on the unique molecular profile of each patient's tumor. In this review, we discuss the scientific milestones of cancer biomarkers and explore future possibilities to improve the management of patients with solid tumors. This progress is primarily attributed to the biological characterization of cancers, advancements in testing methodologies, elucidation of the immune microenvironment, and the ability to profile circulating tumor fractions. Integrating these insights promises to continually advance the precision oncology field, fostering better patient outcomes.

Publication types

Review

MeSH terms

Biomarkers, Tumor*
Humans
Medical Oncology / methods
Neoplasms* / drug therapy
Neoplasms* / therapy
Precision Medicine* / methods
Tumor Microenvironment

Substances

Biomarkers, Tumor

Abstract

Publication types

MeSH terms

Substances

Grants and funding